Thermo Fisher Scientific stock forecast
The weighted forecast is $633.20 in October 2027, $658.58 in October 2028, and $681.35 in October 2029, with the base case at 53% probability. It hinges on broader organic recovery, profitable acquisition integration, and enough cash generation to support investment and shareholder returns.
Where could Thermo Fisher Scientific’s shares be by 2029?
The bear case has 27% probability. The base case has 53%; the bull case has 20%. On October 21, 2026, third-quarter results test whether organic growth is tracking management’s expected second-half pace of roughly 4% and whether cash generation is improving. Decisive evidence includes repeat bioproduction orders—making medicines or their ingredients with living cells—PPD awards converting into paid work, and Clario customers adopting combined services. Clario’s $125 million fixed payment is due in January 2027. By its fifth anniversary, the test is whether expected synergies—savings or added earnings expected when combined businesses work together—have produced $175 million of annual adjusted operating income.
The weighted value is $633.20 in October 2027, a 4% loss including dividends. It reaches $658.58 in October 2028, broadly flat including dividends. By October 2029, the weighted value is $681.35, a 4% gain.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 27 % | 500.21 (-24 %) | 474.61 (-28 %) | 452.29 (-31 %) |
| Base | 53 % | 654.51 (-1 %) | 681.19 (+3 %) | 707.59 (+8 %) |
| Bull | 20 % | 756.25 (+15 %) | 847.04 (+29 %) | 921.02 (+40 %) |
| Weighted | 100 % | 633.20 (-4 %) | 658.58 (+0 %) | 681.35 (+4 %) |
What has to go right for Thermo Fisher Scientific?
Base revenue starts at $47,750 million in 2026. It grows 5% annually. Margins rise from 14.5% in 2027 to 14.9% in 2029. Base earnings therefore reach $7,270 million in 2027 and $8,237 million in 2029; the middle year is $7,740 million. The bear case uses low-single-digit growth and margins around 13.4%–13.5%, producing $6,575 million in 2027 and $6,880 million in 2029. The bull case uses 7% annual growth and margins rising from 15.0% to 16.0%, producing $7,664 million and $9,360 million. Q2 organic growth reached 5% across all four segments, supporting the base, but earlier organic growth was negative in 2023 and flat in 2024.
The bull case requires several successes at once. Research and manufacturing demand broadens, repeat bioproduction orders return, PPD and Clario convert work profitably, and cross-selling improves margins and cash flow. The bull value is $756.25 in 2027. It reaches $921.02 in 2029, including dividends. Its probability is 20% because sustained 7% growth, margin expansion, deleveraging and acquisition returns all remain uncertain.
How much cash does Thermo Fisher Scientific really make?
Thermo Fisher remains a strong cash generator, but its earnings recovery did not produce stronger free cash flow in 2025.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 7,818 | 8,667 | 8,406 | 9,154 | 9,312 |
| − Capital spending | 1,525 | 1,400 | 1,479 | 2,243 | 2,523 |
| = Free cash flow | 6,293 | 7,267 | 6,927 | 6,911 | 6,789 |
| − Stock pay | 310 | 301 | 278 | 307 | 230 |
| = Real free cash flow | 5,983 | 6,966 | 6,649 | 6,604 | 6,559 |
| Real free cash flow, % of revenue | 13.4% | 16.2% | 15.5% | 14.7% | 16.7% |
What does an investor pay for Thermo Fisher Scientific today?
| Today (Oct 12, 2026) | |
|---|---|
| Share price | 662.09 |
| P/E, last 12 months (calculated) | 35.6x |
| P/E, next 12 months (calculated) | 24.1x |
| Free cash flow yield (calculated) | 2.6% |
| Real free cash flow yield (calculated) | 2.4% |
| Dividend yield (calculated) | 0.3% |